|Dr. Troy Edward Wilson||Chairman, CEO & Pres||908.26k||N/A||1969|
|Dr. Marc Grasso||CFO & Chief Bus. Officer||630.86k||N/A||1973|
|Ms. Kathleen Ford||Chief Operating Officer||492.28k||N/A||1947|
|Mr. James E. Basta J.D., Esq.||Chief Legal Officer, Chief Compliance Officer & Corp. Sec.||168.94k||N/A||1966|
|Mr. Pete De Spain||VP of Investor Relations & Corp. Communications||N/A||N/A||N/A|
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, and other hematologic malignancies. It is also developing KO-947, a small molecule inhibitor of extracellular signal related kinase used for the treatment of patients with tumors that have dysregulated activity due to mutations or other mechanisms in the mitogen-activated protein kinase pathway; and KO-539, a small molecule inhibitor of the menin-mixed lineage leukemia protein-protein interaction. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.
Kura Oncology, Inc.’s ISS Governance QualityScore as of December 9, 2019 is 9. The pillar scores are Audit: 2; Board: 9; Shareholder Rights: 8; Compensation: 10.